Striverdi Exercise Trials Tried, But Failed, To Control For Non-Disease Impacts
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA questioned adherence to, and effectiveness of, measures aimed at minimizing exercise test performance variability in the trial Boehringer Ingelheim conducted to support exercise-related labeling claims for the COPD drug.